Meeting
2019 Gastrointestinal Cancers Symposium
High-serum blood sugar level significantly enhances oxaliplatin resistance in stage III colorectal cancer patients.
Authors
Jaw-Yuan Wang
Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 532)
DOI
10.1200/JCO.2019.37.4_suppl.532
Abstract #
532
Poster Bd #
E15
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world adoption of 3 months of adjuvant oxaliplatin chemotherapy in patients with stage III colorectal cancer (CRC).
First Author: Tharani Krishnan
Poster
2021 Gastrointestinal Cancers Symposium
Adjuvant chemotherapy (AC) choices: An analysis of elderly Australian patients with stage III colorectal cancer (CRC).
First Author: Oliver Piercey
Poster
2020 ASCO Virtual Scientific Program
TRACC: Tracking mutations in cell-free DNA to predict relapse in early colorectal cancer—A randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC).
First Author: Gayathri Anandappa
Poster
2020 Gastrointestinal Cancers Symposium
Systemic inflammation, adjuvant chemotherapy, and survival in stage III colorectal cancer: Results from the ScotScan Colorectal Cancer Collaborative.
First Author: James Hugh Park